Ratings for DexCom (NASDAQ:DXCM) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ...

Dexcom has rebounded since my last update, but I maintain a 'Hold' rating due to continued overvaluation and limited upside potential. Growth remains solid, especially in sensors and U.S. expansion, ...

Type 2 diabetes patients who take a GLP-1 such as Ozempic or Wegovy are associated with higher usage of continuous glucose monitors, Dexcom said Sept. 5, according to an Investor’s Business Daily ...